Table 1.
Clinical characteristics at baseline
| Romosozumab | Denosumab | |||
|---|---|---|---|---|
| Variable | ND | BPs | ND | BPs |
| Number | 43 | 38 | 38 | 35 |
| Age, years | 75.3 (1.2) | 73.7 (1.7) | 71.8 (1.4) | 74.4 (1.5) |
| BMI*,†, kg/m2 | 22.1 (0.6) | 20.0 (0.6) | 22.7 (0.5) | 22.2 (0.6) |
| Duration of pretreatment*, months | NA | 26.2 (3.9) | NA | 43.8 (5.9) |
| Prior active vitamin D3 use | 21 patients | 24 patients | 10 patients | 23 patients |
| History of fragility fractures | 34 patients | 22 patients | 21 patients | 23 patients |
| Ca, mg/dL | 9.51 (0.08) | 9.56 (0.09) | 9.47 (0.06) | 9.58 (0.07) |
| eGFR, mL/min/1.73mm2 | 65.8 (2.4) | 68.4 (2.7) | 73.4 (2.3) | 69.2 (3.2) |
| P1NP†, ng/mL | 62.7 (5.9) | 30.2 (4.6) | 56.3 (5.4) | 21.6 (2.0) |
| TRACP-5b†, mU/dL | 497.6 (37.2) | 285.5 (28.5) | 451.0 (27.2) | 279.5 (20.2) |
| 25(OH)D, ng/mL | 15.3 (0.8) | 17.5 (0.9) | 17.7 (1.0) | 17.0 (1.2) |
| Intact PTH, pg/mL | 42.2 (3.4) | 32.8 (4.1) | 37.1 (1.1) | 36.8 (2.4) |
| %YAM Lumbar, % | 71.5 (1.9) | 68.2 (2.7) | 68.5 (2.1) | 71.7 (2.1) |
| %YAM FN, % | 62.5 (2.0) | 62.1 (1.6) | 61.8 (1.6) | 62.2 (1.6) |
| %YAM TH, % | 69.6 (2.2) | 67.5 (1.8) | 68.0 (1.7) | 65.9 (1.9) |
Mean (standard error of the mean). *: P < 0.05 romosozumab vs. denosumab, †: P < 0.05 ND vs. BP group
ND naïve or vitamin D, BPs bisphosphonates, BMI body mass index, Ca calcium, Cr creatinine, eGFR estimated glomerular filtration rate, P1NP total type 1 procollagen-N-propeptide, TRACP-5b tartrate-resistant acid phosphatase 5b, 25(OH)D 25-hydroxy vitamin D, PTH parathyroid hormone, YAM young adult mean, FN femoral neck, TH total hip